CASTRES, France, June 28, 2010 /PRNewswire/ -- Mr Jean-Pierre Garnier will step down on
"The Company is in excellent health, and is poised to experience a bright future ; I am glad to have contributed to its
Mr. Pierre Fabre thanked Mr Jean-Pierre Garnier for his "commitment and the excellent work performed" and stated that "his contribution over the past two years has been of the utmost benefit to the Company".
The new governance, which will continue in the spirit of the current organisation, will be announced in the near future.
About Pierre Fabre group : The Pierre Fabre Group, the second largest independent French pharmaceutical company and leader in the field of in-pharmacy dermocosmetics, employs about 10,000 people worldwide, including 1,400 R&D staff, and generates a turnover of EUR 1.8 billion. In 2009, Pierre Fabre Medicament dedicated 28% of its annual turnover to R&D in four priority therapeutic areas in public health: oncology, central nervous system, dermatology, cardio-vascular/metabolism. To learn more about Pierre Fabre, please refer to http://www.pierre-fabre.com. Press Contact : Djamila Hazene-Kedjem [email protected] +33(0)1-49-10-81-72 / +33(6)89-45-87-95
SOURCE Groupe Pierre Fabre
Subscribe to our Free Newsletters!
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...View All